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INTRODUCTION
Most of our knowledge on the modulation of the
cellular surface phenotypes associated with NK-cell
activation is based mostly on in vitro studies. In
accordance, it has been shown that activated NK-cells
express a number of molecules that are absent in
non-activated NK-cells, and that NK-cell activation
results in either down-regulation or up-regulation of
different receptors constitutively expressed by resting
NK-cells, whereas the surface levels of other
molecules remain stable (1-13).
In order to define the reactive phenotypes after acute
and chronic NK-cell activation in vivo, we have
analyzed by four-color flow cytometry the immuno-
phenotype of blood CD56+low NK-cells in normal
individuals (14), in patients with acute viral infections
and in patients with either chronic infections or tumors
(15) (Fig. 1). This strategy allowed us to characterize
different subsets of normal NK-cells, corresponding to
early and late activation-related stages (15), to compare
reactive NK-cell phenotypes with those observed on 
T-cells (16) and to identify abnormal NK-cell leukemia-
associated phenotypes (17).
NORMAL AND REACTIVE NK-CELL PHENOTYPES
Normal blood CD56+low NK-cells 
Although a great inter-individual variability is found
in normal individuals due to the presence of different
NK-cell populations in different maturation and
activation states, the majority of the CD56+low NK-cells
present in normal blood have a CD2-/+low, CD7+high,
HLA-DR- and CD45RO- phenotype (14). Most of these
cells are CD11b+/CD38+ and homogeneously express
high levels of CD11a and CD45RA, whereas CD11c
and CD57 are heterogeneously expressed in a
variable fraction of CD56+low cells.
CD56+low NK-cells from patients with acute viral
infection
Recently activated CD56+low NK-cells are present at
high frequency in the blood of patients with acute viral
infection (15). They have a pattern of expression of
CD2 and CD7 similar to that observed in resting
mature CD56+low NK-cells, except that a higher
percentage of CD2+ NK-cells and a slightly higher
intensity of CD7 expression are found. CD2+low/
CD7+high CD56+low NK-cells probably originate from
CD2-/CD7+high CD56+low NK-cells upon stimulation,
through de novo expression of CD2 molecules on the
cell surface. Recently activated CD56+low NK-cells
typically show strong reactivity for CD38 and express
high levels of HLA-DR. At that phase, there is also
down-regulation of CD45RA, a phenomenon that is
transiently accompanied by co-expression of CD45RO
in variable proportions of cells. CD11a levels are
increased, whereas expression of CD11b is
decreased. Moreover, these CD56+low NK-cells
express dimly and heterogeneously CD11c while they
are either negative or dimly positive for CD57.
CD56+low NK-cells from patients with chronic infections
and tumors
Chronically activated CD56+low NK-cells shown
unique phenotypic features (15), including up-
regulation of CD2, which becomes homogeneous
(CD2+HIGH), and down-regulation of CD7, which
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Fig. 1 - Immunophenotypic
analysis of blood CD56+low
NK-cells in normal indivi-
duals (A), patients with acute
viral infection (B) and pa-
tients with NK-cell lympho-
cytosis secondary to in-
fections or tumors (C). APC-
conjugated anti-CD3 and PE-
Cy5- conjugated anti-CD56
were used in combination
with the following pairs of
FITC- / PE- conjugated mo-
noclonal antibodies directed
against T- and NK-associated
antigens: CD2/CD7, CD57/
CD11c, CD38/ CD11b, CD11a/
HLA-DR, CD45RA/ CD45RO.
Results are expressed as
percentage of positive cells,
mean fluorescence intensity
(arbitrary relative linear units
scaled from 0 to 10,000) and
coefficient of variation. Bars
represent the mean values
and the vertical lines repre-
sent the standard deviation.
The statistical significance
of differences observed
between groups was evalua-
ted using the Mann-Whitney
U-test. P-values less than
0.05 were considered to be
associated with statistical
significance. ns, not statisti-
cally significant.
becomes heterogeneous (CD7-/+low). In contrast to
recently activated CD56+low NK-cells, chronically
activated CD56+low NK-cells are CD38-/+low and
CD11b-/+low and express high and homogeneous
levels of CD57, while CD11c expression is dim and
heterogeneous. At this stage, most NK-cells have
already rever ted into their or iginal HLA-DR-
/CD45RA+/CD45RO- phenotype, although a variable
proportion of HLA-DR+ and/or CD45RO+ NK-cells can
still be found in some individuals.
DIFFERENCES AND SIMILARITIES BETWEEN REACTIVE
NK-CELL AND T-CELL PHENOTYPES
Patients with infectious mononucleosis show a
massive expansion of CD8+ TCRalpha/beta+ T-cells,
the majority of which display an immunophenotype
compatible with recent T-cell activation (16):
CD2+high, CD7-/+low, CD11a+high, CD38+high, HLA-DR+,
CD45RO+high, CD45RA-/+low, CD11b-/+low, CD11c-/+low,
CD57-. Additionally, the levels of CD3, CD5, CD28
and CD62L molecules are decreased compared to
those found in normal individuals. Late-activation
antigens, such as CD57, were found in small
propor tions of CD8+ TCRalpha/beta+ T-cells.
Increased numbers of activated CD4+ TCRalpha/beta+
and TCRgamma/delta+ T-cells are also observed in
some patients. Evidence for activation of CD4+
TCRalpha/beta+ and TCRgamma/delta+ T-cells rely on
changes similar to those descr ibed for CD8+
TCRalpha/beta+ T-cells.
Curiously, most of the immunophenotypic changes
that occur after NK-cell activation are similar to that
observed on T-cells, although different kinetics were
observed in some markers. For instance up-regulation
of CD11c, CD38 and CD45RO are transiently
observed in early T- and NK-cell activation stages, as
do de novo expression of HLA-DR molecules;
modulation of CD2 and CD7 expression occurs in
both cases, consisting in up-regulation of CD2 and
down regulation of CD7 molecules, which seems to
take place at a latter stage during NK-cell activation,
as compared to that occurring on T-cells; down-
regulation of CD7 expression is probably preceded by
a transient up-regulation of this molecule in both
cases; CD57 behaves as a late activation marker for
both T- and NK-cells.
ABERRANT NK-CELL PHENOTYPES
We have recently repor ted on the immuno-
phenotypic features of a particular type of chronic NK-
cell leukemia, whose NK-cells were either CD56- or
expressed very low levels of CD56 (CD56-/+low NK-
cells), in the context of an aberrant activation-related
mature phenotype (17). CD56-/+low NK-cells display
several unusual immunophenotypic features.
Accordingly, besides being CD56-/+low, they are
CD11b-/+low (heterogeneous), CD7-/+low (heteroge-
neous), CD2+ (homogeneous), CD11c+high (homo-
geneous), CD38-/+low (heterogeneous), CD94+high
(heterogeneous) and HLA-DR+.
Some of the immunophenotypic differences found
between normal and CD56-/+dim NK-cells – i.e. over-
expression of CD11c and HLA-DR and down-
regulation of CD45RA accompanied in some cases by
co-expression of CD45RO in a variable fraction of NK-
cells - do in fact reproduce the immunophenotypic
changes that typically occur on recently activated
CD56+low NK-cells, whereas other – i.e. increased
CD2 expression and decreased and heterogeneous
expression of CD7, CD11b and CD38 – are similar to
those typically observed in conditions of chronic NK-
cell stimulation. In spite of these similarities between
CD56-/+low NK-cells and either recently- or chronically-
activated CD56+low NK-cells, major differences are
observed in the pattern of expression of some
markers. Accordingly, CD56-/+low NK-cells have higher
and more homogenous expression of CD11c, greater
percentages of CD57+ cells and lower levels of HLA-
DR as compared to recently activated NK-cells.
Additionally, CD2 expression is more homogeneous,
down-regulation of CD7 and CD11b is more
pronounced and CD7 expression is even more
heterogeneous on CD56-/+low NK-cells than on
chronically activated CD56+low NK-cells. Moreover,
disagreement between down-regulation of CD11b and
CD38 expression, consisting on a CD11b-/CD38+
phenotype, is frequently found in CD56-/+dim NK-cells
but not on “chronically” activated CD56+low NK-cells.
Such aberrant activation-related immunophenotype
was the very first argument supporting the mono-
clonal nature of these CD56-/+low NK-cells, which was
subsequently confirmed in female patients using the
human androgen receptor gene polymerase chain
reaction -based assay.
CONCLUDING REMARKS
The major ity of changes that have been do-
cumented upon NK-cell activation in vitro are also
reproducible in vivo and define phenotypic patterns
associated to the early/acute- and late/chronic-
phases of NK-cell activation.
Early activation-related NK-cell phenotypes are
found in patients with acute viral infection whereas in
only a minor proportion of patients with chronic
infections and tumors and normal healthy individuals.
Similarly, chronically-activated NK-cells are over-
represented in patients with NK-cell lymphocytosis
associated to conditions in which the underlying
stimuli persist for a long time, although they could also
be found at lower numbers in a few percentage of
patients with acute infections as well as in normal
individuals.
Finally, by understanding the sequence of the
immunophenotypic changes occurring after NK-cell
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activation, we are able to identify aberrant
immunophenotypic patterns and to distinguish
reactive NK-cell lymphocytosis from NK-cell leukemia
cases.
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